June 2022
Volume 63, Issue 7
Open Access
ARVO Annual Meeting Abstract  |   June 2022
Aflibercept Intravitreal Injection for Myopic Choroidal Neovascularization - 5 years follow up
Author Affiliations & Notes
  • Joao J Nassaralla
    Retina and Vitreous, Instituto de Olhos de Goiânia, Goiânia, Goiás, Brazil
  • Arthur Nassaralla
    Retina and Vitreous, Centro Oftalmológico de Minas Gerias, Belo Horizonte, Minas Gerais, Brazil
  • Footnotes
    Commercial Relationships   Joao Nassaralla None; Arthur Nassaralla None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2022, Vol.63, 3775 – F0196. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Joao J Nassaralla, Arthur Nassaralla; Aflibercept Intravitreal Injection for Myopic Choroidal Neovascularization - 5 years follow up. Invest. Ophthalmol. Vis. Sci. 2022;63(7):3775 – F0196.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Follow up results of aflibercept intravitreal injecton (AII) in choroidal neovascularization secondary a pathologic myopia (MN) after 5 years.

Methods : 15 eyes wiht MN were trated with 2mg AII. BVVA, macular thickness on OCT and FA were evaluated. Follow-up were 5 years

Results : The mean were: age: 25yrs, refractive error: -10.75D and macular thickness decreased from 352 to 230 micrometers. At 12 months post -treatment mean BCVA increased from 20/100 to 20/50. Only 1 patient lost 35 letters; other 14 increased or stabilized their VA

Conclusions : These short-term results suggest thet AII are effective and safe and useful in patients with MN

This abstract was presented at the 2022 ARVO Annual Meeting, held in Denver, CO, May 1-4, 2022, and virtually.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×